Bicara Therapeutics Inc. Operating Cash Flow
Bicara Therapeutics Inc. (BCAX) reported Operating Cash Flow of -$81.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Bicara Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$44.21M.
- Bicara Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$37.51M.
- Bicara Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$23.89M.
- Bicara Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$29.25M.
- Bicara Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$106.83M.
- Bicara Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$74.75M.
- Bicara Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$45.63M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$44.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$81.71M 10-Q · filed 2026-08-11 | -$105.60M derived: sum of 3 quarters · filed 2026-08-11 | -$134.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$37.51M 10-Q · filed 2026-05-11 | -$61.39M derived: sum of 2 quarters · filed 2026-05-11 | -$90.64M derived: sum of 3 quarters · filed 2026-05-11 | -$116.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$23.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$53.13M derived: sum of 2 quarters · filed 2026-03-30 | -$78.73M derived: sum of 3 quarters · filed 2026-08-11 | -$106.83M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$29.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$54.84M derived: sum of 2 quarters · filed 2026-08-11 | -$82.95M 10-Q · filed 2025-11-10 | -$112.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$25.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$53.70M 10-Q · filed 2026-08-11 | -$83.73M derived: sum of 3 quarters · filed 2026-08-11 | -$100.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$28.11M 10-Q · filed 2026-05-11 | -$58.14M derived: sum of 2 quarters · filed 2026-05-11 | -$75.36M derived: sum of 3 quarters · filed 2026-05-11 | -$88.27M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$30.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$47.26M derived: sum of 2 quarters · filed 2026-03-30 | -$60.16M derived: sum of 3 quarters · filed 2026-03-30 | -$74.75M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$17.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$30.13M derived: sum of 2 quarters · filed 2025-11-10 | -$44.72M 10-Q · filed 2025-11-10 | -$52.76M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$12.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$27.50M 10-Q · filed 2025-08-12 | -$35.53M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$14.59M 10-Q · filed 2025-05-13 | -$22.62M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$45.63M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$37.59M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |